国家医保局发布2025年国家基本医保目录及商保创新药目录调整通过形式审查的申报药品专家评审阶段性结果查询公告

Core Points - The National Healthcare Security Administration (NHSA) has released the interim results of expert reviews for the 2025 National Basic Medical Insurance Directory and the Commercial Insurance Innovative Drug Directory [1] - Companies can access the evaluation results through the National Medical Insurance Service Platform, specifically in the "2025 Basic Medical Insurance Directory and Commercial Insurance Innovative Drug Directory Adjustment" module [1] - The evaluation results categorize drugs as "proposed for negotiation addition," "proposed for competitive bidding addition," or "proposed for price negotiation," indicating eligibility for negotiation or bidding but not confirmation of inclusion in the directories [1]